{"gene":"CCL4","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":1995,"finding":"CCL4 (MIP-1β), together with RANTES and MIP-1α, was identified as a major HIV-suppressive factor produced by CD8+ T cells. Recombinant CCL4 induced dose-dependent inhibition of HIV-1, HIV-2, and SIV infection, and neutralizing antibodies against all three chemokines completely blocked HIV-suppressive activity in CD8+ T cell supernatants.","method":"Protein purification from CD8+ T cell culture supernatants, sequence identification, recombinant protein functional assay, neutralizing antibody blockade","journal":"Science","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (purification, sequencing, recombinant protein assay, antibody neutralization), widely replicated finding","pmids":["8525373"],"is_preprint":false},{"year":1993,"finding":"CCL4 (MIP-1β), when immobilized on proteoglycan (heparin-BSA conjugate or CD44 proteoglycan), induces T cell adhesion to VCAM-1, preferentially augmenting adhesion of CD8+ T cells. CCL4 is present on lymph node endothelium in vivo, suggesting proteoglycan-mediated presentation on endothelial surfaces.","method":"In vitro T cell adhesion assay with immobilized chemokine on proteoglycan substrates, immunolocalization of CCL4 on lymph node endothelium","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct functional adhesion assay plus in vivo localization, published in Nature with broad replication","pmids":["7678446"],"is_preprint":false},{"year":1993,"finding":"CCL4 (MIP-1β) acts as a potent chemoattractant for activated T lymphocytes, with preferential chemotactic activity toward CD4+ T cells, and enhances T cell binding to endothelial cell monolayers.","method":"In vitro microchemotaxis (Boyden chamber) assay with recombinant human MIP-1β on activated and resting T cell subsets; endothelial adhesion assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated by multiple independent labs using in vitro chemotaxis assays","pmids":["7682337","7684437"],"is_preprint":false},{"year":1993,"finding":"CCL4 (MIP-1β) preferentially attracts CD4+ T lymphocytes (with some preference for naive CD45RA phenotype) in microchemotaxis assays, while CCL3 (MIP-1α) has broader lymphocyte chemoattractant activity including B cells and cytotoxic T cells.","method":"In vitro microchemotaxis assay comparing recombinant MIP-1α and MIP-1β across lymphocyte subpopulations","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct comparative functional assay, replicated across independent labs","pmids":["7684437","7682337"],"is_preprint":false},{"year":1991,"finding":"CCL4 (MIP-1β) blocks the suppressive activity of MIP-1α on myeloid progenitor cell (BFU-E, CFU-GEMM, CFU-GM) colony formation. Pulse treatment showed CCL4 must act before or simultaneously with MIP-1α; the antagonism is specific (CCL4 does not block H-ferritin suppression).","method":"Bone marrow colony formation assay with recombinant murine MIP-1β and MIP-1α, pulse-treatment experiments, specificity controls with H-ferritin","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean in vitro functional assay with specificity controls, single lab","pmids":["1918979"],"is_preprint":false},{"year":1995,"finding":"CCL4 (MIP-1β) elicits weak monocyte chemotaxis and minimal degranulation (N-acetyl-β-D-glucosaminidase release) compared to MCP-1 and MIP-1α. Cross-desensitization experiments using intracellular Ca2+ changes and binding competition with radiolabeled MIP-1α showed that MIP-1β shares receptors with RANTES and MIP-1α but not with MCP-1/2/3.","method":"In vitro monocyte chemotaxis, degranulation, Ca2+ flux, receptor desensitization, and radiolabeled ligand competition binding assays","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal biochemical assays in a single rigorous study establishing receptor sharing","pmids":["7531149"],"is_preprint":false},{"year":2001,"finding":"CCL4 is the most potent chemoattractant for CD4+CD25+ regulatory T cells produced by activated B cells and professional APCs. Depletion of CCL4 led to a deregulated humoral response and production of autoantibodies, establishing CCL4 as a mediator of regulatory T cell recruitment to B cells and APCs.","method":"Gene expression profiling to identify chemokines, chemotaxis assays, CCL4 depletion experiments, analysis of humoral immune response","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — functional in vivo depletion plus in vitro chemotaxis, published in Nature Immunology","pmids":["11702067"],"is_preprint":false},{"year":2000,"finding":"CCL4 (MIP-1β) can function as a monomer for CCR5 binding and activation. Monomeric mutants (P8A, N-terminally truncated MIP(9)) retained CCR5 binding (Ki ~480–600 pM) and the ability to activate CCR5 (induce Ca2+ release). Phe13, the residue immediately after the conserved CC motif, is a key determinant for CCR5 binding; substitution with Tyr, Leu, Lys, or Ala reduced both binding affinity and receptor activation.","method":"NMR spectroscopy, analytical ultracentrifugation, CCR5 receptor binding assays, intracellular Ca2+ release assay in CCR5-transfected CHO cells, mutagenesis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution with mutagenesis, NMR structural validation, and functional receptor assays in a single study","pmids":["10727234"],"is_preprint":false},{"year":2002,"finding":"The naturally occurring N-terminally truncated form of CCL4 (MIP-1β(3-69)), secreted by activated human peripheral blood lymphocytes, retains the ability to downregulate CCR5 surface expression and inhibit CCR5-mediated HIV-1 entry. Unlike full-length CCL4, MIP-1β(3-69) also triggers Ca2+ responses via CCR1 and CCR2b, indicating expanded receptor specificity upon truncation.","method":"Affinity purification of native truncated protein from lymphocyte supernatants, mass spectrometry structural confirmation, CCR5 downmodulation assay, HIV entry inhibition assay, Ca2+ signaling assays through CCR1, CCR2b, and CCR5","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — purification of native protein, structural confirmation by MS, multiple functional receptor assays, single lab","pmids":["12070155"],"is_preprint":false},{"year":2004,"finding":"CD26/dipeptidyl-peptidase IV (DPPIV) cleaves full-length CCL4 (MIP-1β) at its N-terminus to generate the truncated form MIP-1β(3-69). Cleavage is blocked by DPPIV inhibitory peptides derived from HIV Tat(1-9) or TAX2-R(1-9). Kinetics of conversion in activated PBLs correlates with cell surface expression of CD26.","method":"Enzymatic cleavage assay with CD26/DPPIV, DPPIV inhibitory peptide blockade in cell culture, correlation of CD26 surface expression with conversion kinetics","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct enzymatic assay with inhibitor controls and cell-based confirmation, single lab","pmids":["15095403"],"is_preprint":false},{"year":2002,"finding":"The N-loop residues Arg18, Lys19, and Arg22 of CCL4 (MIP-1β), along with Pro21, contribute to CCR5 binding through their positive charge. Tyr15 is necessary for proper chemokine folding. Binding determinants are arranged on one surface of the protein. Correlation between binding affinity and functional potency in Ca2+ assays confirms these residues are essential for CCR5 interaction.","method":"Site-directed mutagenesis, NMR spectroscopy (folding analysis), CCR5 receptor binding assay, Ca2+ mobilization functional assay","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis combined with NMR and two functional assays, single lab","pmids":["12427015"],"is_preprint":false},{"year":2010,"finding":"CCL4 (MIP-1β) and CCL3 (MIP-1α) form rod-shaped, double-helical high-molecular-weight polymers as revealed by crystal structures. Polymerization buries receptor-binding sites, and depolymerization mutations enhance CCL3/CCL4 ability to arrest monocytes on activated endothelium but render them ineffective in mouse peritoneal cell recruitment. Insulin-degrading enzyme (IDE) selectively degrades monomeric CCL4/CCL3 but not polymers; decreased IDE expression leads to elevated CCL4 levels in microglial cells.","method":"Crystal structure determination, biophysical analyses (sedimentation, DLS), mathematical modeling, depolymerization mutagenesis, monocyte arrest assays, peritoneal cell recruitment assay, proteomic identification of IDE, IDE knockdown in microglial cells","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus multiple orthogonal biophysical, functional, and cellular assays; single study with comprehensive mechanistic coverage","pmids":["20959807"],"is_preprint":false},{"year":2015,"finding":"Crystal structure of CCL4 shows that Pro8, conserved in CCL4 and CCL3, is critical for oligomerization. The P8A mutation in CCL4 stabilizes a type 1 β-turn at the N-terminus, preventing dimerization by a mechanism distinct from that in CCL3. IDE degrades CCL3 and CCL4 but not CCL18 (which lacks Pro8), providing a structural basis for selective degradation.","method":"Crystal structure determination, small-angle X-ray scattering, mutagenesis (P8A), IDE degradation assays","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with SAXS and functional mutagenesis and enzymatic assays, single lab","pmids":["25636406"],"is_preprint":false},{"year":2009,"finding":"CCL4 (MIP-1β) signaling through CCR5 in primary human macrophages requires an arrestin-dependent multi-kinase complex. CCR5 stimulation by CCL4 triggers Pyk2 and PI3K p85 translocation from cytoplasm to colocalize with Lyn at the plasma membrane, forming a multimolecular complex. Arrestins are recruited into this complex; arrestin knockdown impairs complex formation and abolishes macrophage chemotaxis toward CCL4.","method":"siRNA gene silencing, pharmacological kinase inhibition, co-localization imaging, Co-IP/complex formation assays in primary human macrophages","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown plus pharmacological inhibition plus co-localization in primary human cells, multiple orthogonal approaches","pmids":["19620252"],"is_preprint":false},{"year":1990,"finding":"Cell surface receptors for CCL4 (Act-2) were identified on activated peripheral blood lymphocytes and multiple cell lines (MT-2, HL60, HeLa, K562). The equilibrium dissociation constant (Kd) is 3–12 nM. A blocking polyclonal antiserum was developed that prevents Act-2 receptor binding.","method":"125I-labeled Act-2 radioligand binding assay, equilibrium binding analysis (Kd determination), blocking antiserum development","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct radiolabeled ligand binding with Kd determination and blocking antibody, single lab","pmids":["2193098"],"is_preprint":false},{"year":2013,"finding":"In prostate tumorigenesis, macrophage androgen receptor (AR) upregulates CCL4 secretion, which activates STAT3 in epithelial cells, promoting epithelial-to-mesenchymal transition and downregulation of p53/PTEN. CCL4-neutralizing antibody blocked macrophage-induced tumorigenic signaling, and an AR degradation enhancer (ASC-J9) reduced CCL4 expression and xenograft tumor growth in vivo.","method":"Macrophage-epithelial cell co-culture tumorigenesis model, CCL4 neutralizing antibody, AR degradation enhancer treatment, xenograft in vivo model, PTEN+/- macrophage AR knockout mice","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple in vitro and in vivo models with antibody blockade, single lab","pmids":["23878190"],"is_preprint":false},{"year":2006,"finding":"CCL4 promotes trophoblast migration at the feto-maternal interface. CCR1 and CCR3 (CCL4 receptors) are expressed on extravillous trophoblasts. Trophoblast migration occurred in response to CCL4 in migration assays, and this was attenuated by neutralizing antibodies to CCL4 in endometrial cell-conditioned media.","method":"Immunolocalization of chemokine receptors in human implantation sites, RT-PCR for receptor expression, trophoblast cell line migration assay, neutralizing antibody inhibition","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct migration assay plus receptor localization plus neutralizing antibody, single lab","pmids":["16452465"],"is_preprint":false},{"year":2015,"finding":"miR-125b negatively regulates CCL4 expression in human immune cells (monocytes, naïve CD8 T cells) by targeting the 3'UTR seed sequence of CCL4 mRNA. shRNA knockdown of miR-125b increased CCL4 protein, while transfection of miR-125b reduced CCL4 mRNA and protein following stimulation. Reduced miR-125b in old adults correlates with elevated CCL4.","method":"shRNA knockdown of miR-125b in primary human immune cells, miR-125b overexpression by transfection, 3'UTR seed sequence validation, intracellular CCL4 protein measurement","journal":"Aging cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct gain- and loss-of-function experiments with 3'UTR validation, single lab","pmids":["25620312"],"is_preprint":false},{"year":2017,"finding":"CCL4 secreted by M1 macrophage-derived foam cells induces endothelial-to-mesenchymal transition (EndMT) via CCR5, upregulating TGF-β expression, which increases endothelial permeability and monocyte adhesion. Anti-CCL4 antibody abolished EndMT; CCR5 antagonist and TGF-β knockdown reversed CCL4-induced EndMT.","method":"Protein array to identify CCL4, ELISA, anti-CCL4 antibody neutralization, CCR5 antagonist treatment, TGF-β siRNA knockdown, permeability assay, monocyte adhesion assay","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — antibody neutralization, receptor antagonist, and siRNA knockdown with multiple functional readouts, single lab","pmids":["28656247"],"is_preprint":false},{"year":2021,"finding":"CCL4 signals through CCR5 in blood-brain barrier endothelial cells to cause p38 phosphorylation, actin stress fiber formation, junctional ZO-1 reduction (~60% within 60 min), VE-cadherin internalisation, increased paracellular permeability in vitro and in vivo, and enhanced lymphocyte transmigration across endothelial monolayers.","method":"Western blot (p38 phosphorylation), immunofluorescence (ZO-1, VE-cadherin, F-actin), RITC-dextran flux permeability assay, transendothelial lymphocyte migration assay, in vivo pial microvessel occlusion technique, fluorescein angiography in mouse retinae","journal":"Brain, behavior, & immunity - health","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal functional and cellular assays in vitro and in vivo, single lab","pmids":["34755124"],"is_preprint":false},{"year":2016,"finding":"Hypoxia-conditioned macrophages promote glioblastoma cell invasion via CCL4-CCR5 axis. Hypoxia upregulates CCR5 expression on GBM cells and elevates CCL4 secretion from macrophages via IRF-8. CCL4 from hypoxic macrophage supernatants enhanced GBM invasion and MMP-9 expression, and this effect was mediated through CCR5 signaling.","method":"GBM cell invasion assay, macrophage supernatant treatment, CCR5 expression analysis, CCL4 ELISA, IRF-8 involvement analysis","journal":"Oncology reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, functional assay without direct genetic manipulation of CCL4 or full receptor pathway validation","pmids":["27748906"],"is_preprint":false},{"year":2018,"finding":"CCL4 enhances preosteoclast cell migration and viability via CCR5. RANKL treatment rapidly downregulates CCR5 expression on preosteoclasts via MEK and JNK signaling, and this CCR5 downregulation promotes osteoclastogenesis. IFN-γ recovers CCR5 expression and antagonizes the pro-osteoclastogenic effect.","method":"CCL4 migration and viability assays in preosteoclast cells, CCR5 expression analysis upon RANKL treatment, MEK and JNK pharmacological inhibition, IFN-γ treatment, osteoclast differentiation assay","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — pharmacological inhibition of kinase pathway plus functional differentiation assay, single lab","pmids":["29717113"],"is_preprint":false},{"year":2019,"finding":"CCL4 acts as a chemoattractant for eosinophils. IL-5-stimulated human eosinophils predominantly secrete CCL4. In a mouse model, administration of a CCL4-neutralizing antibody attenuated eosinophilic airway infiltration and airway hyperresponsiveness.","method":"In vitro eosinophil stimulation and CCL4 measurement, in vitro eosinophil chemotaxis assay, in vivo mouse model with CCL4-neutralizing antibody, airway hyperresponsiveness measurement","journal":"Clinical and experimental allergy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro chemotaxis plus in vivo antibody neutralization model, single lab","pmids":["30854716"],"is_preprint":false},{"year":2007,"finding":"CCL4 delivery to NOD mice via plasmid vector protects against type 1 diabetes by suppressing CD8+ T cell recruitment to islets (with decreased CCR5 expression on CD8+ T cells), inducing a Th2-like response in spleen and pancreas, and promoting regulatory T cell activity in draining pancreatic lymph nodes. Antibody neutralization of CCL4 abrogated protection transferred by T cells from IL-4-treated NOD mice.","method":"Plasmid-based in vivo CCL4 delivery, CCL4 antibody neutralization, T cell transfer protection assay, flow cytometry of T cell subsets and CCR5 expression, Th1/Th2 cytokine profiling","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic delivery plus antibody neutralization plus immune phenotyping, single lab","pmids":["17327452"],"is_preprint":false},{"year":2013,"finding":"EBV latent membrane protein 1 (LMP1) upregulates CCL4 (and CCL3) in EBV-infected B cells via Jun N-terminal protein kinase (JNK) activation. Autocrine CCL4 and CCL3 are required for lymphoblastoid cell line (LCL) survival and proliferation; shRNA knockdown or neutralizing antibodies to CCL4/CCL3 suppressed cell proliferation and caused apoptosis.","method":"Cytokine antibody arrays, EBV-infection/LMP1 expression model, JNK inhibitor treatment, shRNA knockdown, neutralizing antibodies to CCL4/CCL3, proliferation and apoptosis assays","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — shRNA knockdown and neutralizing antibody with mechanistic pathway (LMP1-JNK-CCL4) established, single lab","pmids":["23760235"],"is_preprint":false},{"year":2021,"finding":"CCL4 promotes osteosarcoma cell migration via CCR5, activating FAK, AKT, and HIF-1α signaling pathways, which downregulate miR-3927-3p, leading to upregulation of integrin αvβ3. Pharmacological inhibition of CCR5 with maraviroc prevented CCL4-induced integrin αvβ3 upregulation and cell migration.","method":"CCL4/CCR5 signaling pathway analysis, FAK/AKT/HIF-1α inhibitor treatment, miR-3927-3p expression analysis, integrin αvβ3 expression assay, CCR5 antagonist (maraviroc) treatment, cell migration assay","journal":"International journal of molecular sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological inhibition only without direct genetic manipulation of CCL4 pathway components, single lab","pmids":["34884541"],"is_preprint":false},{"year":1999,"finding":"CCL4 (MIP-1β) does not bind to or signal through CCR8 at physiologically relevant concentrations. CCL4 did not bind CCR8 on stably transfected cells or on human Th2 cells, did not induce CCR8-mediated chemotaxis, and did not desensitize I-309-dependent Ca2+ mobilization through CCR8.","method":"CCR8-transfected cell line binding assay, chemotaxis assay, Ca2+ mobilization and receptor desensitization assay, binding on in vitro differentiated human CD4+ Th2 cells","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal receptor assays establishing a negative result with appropriate controls, single lab","pmids":["10540332"],"is_preprint":false},{"year":1993,"finding":"Microinjection of CCL4 (MIP-1β) into the anterior hypothalamic preoptic area of rats evokes a monophasic fever (mean maximum ~2.1°C increase) and significantly attenuates food intake over 24 hours, demonstrating direct central nervous system actions on thermoregulation and feeding.","method":"Stereotaxic microinjection into rat anterior hypothalamus/preoptic area, body temperature telemetry, food and water intake monitoring","journal":"Neurochemical research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pharmacological administration without receptor identification or pathway mechanistic follow-up","pmids":["8510794"],"is_preprint":false}],"current_model":"CCL4 (MIP-1β/Act-2/SCYA4) is a CC chemokine that signals primarily through CCR5 (and, when N-terminally truncated by CD26/DPPIV, also through CCR1 and CCR2b) to drive chemotaxis of activated CD4+ and CD8+ T cells, monocytes/macrophages, regulatory T cells, and eosinophils; it inhibits HIV-1/HIV-2/SIV infection by competing for CCR5; it forms reversible rod-shaped double-helical polymers that protect it from selective degradation by insulin-degrading enzyme while burying its receptor-binding site; its CCR5 binding is mediated by Phe13 and N-loop residues Arg18, Lys19, and Arg22; and upon CCR5 engagement it assembles an arrestin-scaffolded Lyn/Pyk2/PI3K signaling complex to drive macrophage chemotaxis, activates p38-MAPK to disrupt blood-brain barrier tight junctions, and regulates diverse processes including myeloid progenitor suppression (antagonized by CCL3), endothelial-to-mesenchymal transition, regulatory T cell recruitment, osteoclast precursor migration, and EBV-driven B cell survival."},"narrative":{"mechanistic_narrative":"CCL4 (MIP-1β/Act-2) is a CC chemokine that directs the recruitment and adhesion of leukocytes—preferentially activated CD4+ and CD8+ T cells, monocytes, regulatory T cells, and eosinophils—during immune responses, and was identified as a major CD8+ T-cell-derived soluble factor that suppresses HIV-1, HIV-2, and SIV infection by competing for its receptor [PMID:8525373, PMID:7682337, PMID:7684437, PMID:30854716]. It functions chemotactically and, when immobilized on endothelial proteoglycan, promotes T-cell adhesion to VCAM-1, positioning it for leukocyte arrest on activated endothelium [PMID:7678446, PMID:7682337, PMID:7684437]. CCL4 signals principally through CCR5; binding is mediated by Phe13 immediately after the conserved CC motif and by positively charged N-loop residues Arg18, Lys19, and Arg22, with monomeric CCL4 sufficient for CCR5 binding and Ca2+-mobilizing activation [PMID:10727234, PMID:12427015]. CD26/DPPIV cleaves the N-terminus to generate MIP-1β(3-69), which retains CCR5 downmodulation and HIV-entry inhibition while acquiring expanded signaling through CCR1 and CCR2b [PMID:12070155, PMID:15095403]. Downstream of CCR5 in primary macrophages, CCL4 nucleates an arrestin-dependent multikinase complex of Lyn, Pyk2, and PI3K p85 at the plasma membrane that is required for chemotaxis [PMID:19620252]. CCL4 (and CCL3) assemble into rod-shaped double-helical polymers whose formation depends on Pro8 and buries the receptor-binding surface; polymerization protects the chemokine from selective degradation by insulin-degrading enzyme, which cleaves only the monomeric forms [PMID:20959807, PMID:25636406]. Beyond leukocyte trafficking, CCL4–CCR5 signaling drives endothelial-to-mesenchymal transition via TGF-β and disrupts blood-brain-barrier tight junctions through p38 activation and loss of ZO-1/VE-cadherin [PMID:28656247, PMID:34755124], and CCL4 expression is post-transcriptionally restrained by miR-125b [PMID:25620312]. CCL4 also antagonizes CCL3-mediated suppression of myeloid progenitor colony formation and mediates regulatory T-cell recruitment to B cells and APCs [PMID:1918979, PMID:11702067].","teleology":[{"year":1990,"claim":"Establishing that CCL4 acts through specific cell-surface receptors was the first step in defining it as a signaling ligand rather than a generic secreted factor.","evidence":"125I-Act-2 radioligand equilibrium binding on activated PBLs and cell lines with blocking antiserum","pmids":["2193098"],"confidence":"Medium","gaps":["Receptor identity not molecularly defined","Downstream signaling not addressed"]},{"year":1991,"claim":"The finding that CCL4 antagonizes CCL3-mediated myeloid progenitor suppression revealed that closely related MIP-1 chemokines have opposing functional outputs.","evidence":"Bone marrow colony-formation assays with recombinant murine MIP-1β/MIP-1α, pulse treatments, H-ferritin specificity controls","pmids":["1918979"],"confidence":"Medium","gaps":["Receptor mediating antagonism not identified","Single lab, murine system"]},{"year":1993,"claim":"Defining CCL4 as a chemoattractant and adhesion-promoting factor for T-cell subsets, with proteoglycan-dependent endothelial presentation, established its core role in directing lymphocyte trafficking.","evidence":"Boyden-chamber chemotaxis on T-cell subsets, VCAM-1 adhesion assays with proteoglycan-immobilized chemokine, endothelial immunolocalization","pmids":["7682337","7684437","7678446"],"confidence":"High","gaps":["Receptor not yet defined","Molecular basis of adhesion augmentation unresolved"]},{"year":1995,"claim":"Identifying CCL4 as a CD8+ T-cell-derived HIV-suppressive factor and showing it shares receptors with RANTES and MIP-1α connected chemokine receptor usage to antiviral activity.","evidence":"Purification/sequencing from CD8+ T-cell supernatants, recombinant inhibition of HIV-1/2 and SIV, antibody neutralization; cross-desensitization and competition binding versus MCP-1","pmids":["8525373","7531149"],"confidence":"High","gaps":["Specific receptor not yet named in these studies","Mechanism of competition not structurally resolved"]},{"year":2000,"claim":"Mapping Phe13 and N-loop residues and showing monomeric CCL4 is competent for CCR5 binding/activation defined the molecular determinants of receptor engagement.","evidence":"NMR, analytical ultracentrifugation, CCR5 binding and Ca2+ assays in CHO cells, mutagenesis (P8A, MIP(9), Phe13 substitutions, R18/K19/R22, Y15)","pmids":["10727234","12427015"],"confidence":"High","gaps":["Receptor-bound complex structure not determined","Role of oligomerization in vivo unresolved"]},{"year":2002,"claim":"Demonstrating that N-terminal truncation to MIP-1β(3-69) expands receptor specificity to CCR1/CCR2b while retaining anti-HIV CCR5 activity showed how processing reprograms CCL4 function.","evidence":"Native protein purification, mass spec, CCR5 downmodulation, HIV-entry inhibition, Ca2+ signaling via CCR1/CCR2b/CCR5","pmids":["12070155"],"confidence":"High","gaps":["Physiological enzyme not identified in this study","Relative in vivo abundance of truncated form unclear"]},{"year":2004,"claim":"Identifying CD26/DPPIV as the protease generating MIP-1β(3-69) linked surface enzyme expression to in vivo control of CCL4 receptor specificity.","evidence":"Enzymatic cleavage assays, DPPIV inhibitory peptide blockade, correlation of CD26 surface expression with conversion in PBLs","pmids":["15095403"],"confidence":"Medium","gaps":["Single lab","Quantitative contribution to in vivo signaling not established"]},{"year":2009,"claim":"Defining the arrestin-scaffolded Lyn/Pyk2/PI3K complex downstream of CCR5 established the intracellular machinery converting CCL4 binding into macrophage chemotaxis.","evidence":"siRNA silencing, kinase inhibition, co-localization imaging, Co-IP in primary human macrophages","pmids":["19620252"],"confidence":"High","gaps":["Generalizability to other CCL4-responsive cells untested","Order of complex assembly not fully resolved"]},{"year":2010,"claim":"Discovery of double-helical CCL4 polymers and their protection from insulin-degrading enzyme revealed a structural switch controlling chemokine availability and presentation.","evidence":"Crystal structures, sedimentation/DLS, depolymerization mutants, monocyte arrest and peritoneal recruitment assays, IDE identification and microglial knockdown","pmids":["20959807"],"confidence":"High","gaps":["In vivo trigger for polymer/monomer transition unclear","Physiological balance of IDE degradation versus signaling unresolved"]},{"year":2015,"claim":"Pinpointing Pro8 as the structural determinant of oligomerization and selective IDE degradation explained why CCL4/CCL3 but not CCL18 are IDE substrates.","evidence":"Crystal structure, SAXS, P8A mutagenesis, IDE degradation assays; plus miR-125b 3'UTR targeting of CCL4","pmids":["25636406","25620312"],"confidence":"Medium","gaps":["Functional consequence of P8A oligomerization defect in vivo not tested","miR-125b regulation mapped in limited cell types"]},{"year":2021,"claim":"Showing CCL4–CCR5 disrupts endothelial junctions via p38 and drives EndMT via TGF-β extended CCL4 function from leukocyte recruitment to direct modulation of vascular barriers.","evidence":"Western blot, immunofluorescence (ZO-1, VE-cadherin, F-actin), permeability and transmigration assays in vitro and in vivo; CCR5 antagonist and TGF-β siLNA in EndMT model","pmids":["34755124","28656247"],"confidence":"Medium","gaps":["Single lab per study","Relative contribution to disease pathology not established"]},{"year":null,"claim":"How CCL4 polymerization, CD26-mediated truncation, and receptor selection are integrated to set context-specific responses (T-cell trafficking versus tumor, vascular, and bone microenvironments) remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structure of CCL4 bound to CCR5","In vivo determinants of monomer/polymer and full-length/truncated balance unknown","Mechanisms beyond CCR5 in non-immune contexts incompletely defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,2,7,10]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[7,13,19]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,6,22]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,13]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,2,6,22]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,13,19]}],"complexes":[],"partners":["CCR5","CCR1","CCR2B","CD26","IDE","CCL3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P13236","full_name":"C-C motif chemokine 4","aliases":["G-26 T-lymphocyte-secreted protein","HC21","Lymphocyte activation gene 1 protein","LAG-1","MIP-1-beta(1-69)","Macrophage inflammatory protein 1-beta","MIP-1-beta","PAT 744","Protein H400","SIS-gamma","Small-inducible cytokine A4","T-cell activation protein 2","ACT-2"],"length_aa":92,"mass_kda":10.2,"function":"Monokine with inflammatory and chemokinetic properties. Binds to CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-beta induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form MIP-1-beta(3-69) retains the abilities to induce down-modulation of surface expression of the chemokine receptor CCR5 and to inhibit the CCR5-mediated entry of HIV-1 in T-cells. MIP-1-beta(3-69) is also a ligand for CCR1 and CCR2 isoform B","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P13236/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCL4","classification":"Not Classified","n_dependent_lines":62,"n_total_lines":1047,"dependency_fraction":0.05921680993314231},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCL4","total_profiled":1310},"omim":[{"mim_id":"621133","title":"OPIOID GROWTH FACTOR RECEPTOR-LIKE PROTEIN 1; OGFRL1","url":"https://www.omim.org/entry/621133"},{"mim_id":"611387","title":"CXC CHEMOKINE LIGAND 17; CXCL17","url":"https://www.omim.org/entry/611387"},{"mim_id":"610369","title":"HEAT-SHOCK 70-KD PROTEIN 14; HSPA14","url":"https://www.omim.org/entry/610369"},{"mim_id":"609888","title":"LEPROSY, SUSCEPTIBILITY TO, 1; LPRS1","url":"https://www.omim.org/entry/609888"},{"mim_id":"609423","title":"HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/609423"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":181.9}],"url":"https://www.proteinatlas.org/search/CCL4"},"hgnc":{"alias_symbol":["MIP-1-beta","Act-2","AT744.1"],"prev_symbol":["LAG1","SCYA4"]},"alphafold":{"accession":"P13236","domains":[{"cath_id":"2.40.50.40","chopping":"35-92","consensus_level":"medium","plddt":96.5629,"start":35,"end":92}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P13236","model_url":"https://alphafold.ebi.ac.uk/files/AF-P13236-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P13236-F1-predicted_aligned_error_v6.png","plddt_mean":87.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCL4","jax_strain_url":"https://www.jax.org/strain/search?query=CCL4"},"sequence":{"accession":"P13236","fasta_url":"https://rest.uniprot.org/uniprotkb/P13236.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P13236/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P13236"}},"corpus_meta":[{"pmid":"8525373","id":"PMC_8525373","title":"Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.","date":"1995","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8525373","citation_count":2552,"is_preprint":false},{"pmid":"7678446","id":"PMC_7678446","title":"T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7678446","citation_count":848,"is_preprint":false},{"pmid":"7682337","id":"PMC_7682337","title":"Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta.","date":"1993","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7682337","citation_count":745,"is_preprint":false},{"pmid":"7684437","id":"PMC_7684437","title":"Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes.","date":"1993","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7684437","citation_count":505,"is_preprint":false},{"pmid":"15565662","id":"PMC_15565662","title":"Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice.","date":"2004","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15565662","citation_count":430,"is_preprint":false},{"pmid":"11702067","id":"PMC_11702067","title":"B cells and professional APCs recruit regulatory T cells via CCL4.","date":"2001","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11702067","citation_count":397,"is_preprint":false},{"pmid":"7531149","id":"PMC_7531149","title":"Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes.","date":"1995","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7531149","citation_count":308,"is_preprint":false},{"pmid":"16452465","id":"PMC_16452465","title":"The chemokines, CX3CL1, CCL14, and CCL4, promote human trophoblast migration at the feto-maternal interface.","date":"2006","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/16452465","citation_count":173,"is_preprint":false},{"pmid":"27452039","id":"PMC_27452039","title":"Mechanisms of CCl4-induced liver fibrosis with combined transcriptomic and proteomic analysis.","date":"2016","source":"The Journal of toxicological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27452039","citation_count":157,"is_preprint":false},{"pmid":"7545093","id":"PMC_7545093","title":"Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells.","date":"1995","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7545093","citation_count":153,"is_preprint":false},{"pmid":"9570566","id":"PMC_9570566","title":"Cytokine induction of MIP-1 alpha and MIP-1 beta in human fetal microglia.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9570566","citation_count":140,"is_preprint":false},{"pmid":"20959807","id":"PMC_20959807","title":"Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme.","date":"2010","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/20959807","citation_count":138,"is_preprint":false},{"pmid":"23043521","id":"PMC_23043521","title":"CCl4-induced hepatotoxicity: protective effect of rutin on p53, CYP2E1 and the antioxidative status in rat.","date":"2012","source":"BMC complementary and alternative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23043521","citation_count":136,"is_preprint":false},{"pmid":"32060843","id":"PMC_32060843","title":"CCL4 Signaling in the Tumor Microenvironment.","date":"2020","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/32060843","citation_count":131,"is_preprint":false},{"pmid":"23878190","id":"PMC_23878190","title":"Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23878190","citation_count":131,"is_preprint":false},{"pmid":"12500195","id":"PMC_12500195","title":"Foxf1 +/- mice exhibit defective stellate cell activation and abnormal liver regeneration following CCl4 injury.","date":"2003","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/12500195","citation_count":117,"is_preprint":false},{"pmid":"26218279","id":"PMC_26218279","title":"Quercetin protects mouse liver against CCl₄-induced inflammation by the TLR2/4 and MAPK/NF-κB pathway.","date":"2015","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26218279","citation_count":116,"is_preprint":false},{"pmid":"10727234","id":"PMC_10727234","title":"CC chemokine MIP-1 beta can function as a monomer and depends on Phe13 for receptor binding.","date":"2000","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10727234","citation_count":97,"is_preprint":false},{"pmid":"20211986","id":"PMC_20211986","title":"FXR regulates liver repair after CCl4-induced toxic injury.","date":"2010","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20211986","citation_count":93,"is_preprint":false},{"pmid":"1918979","id":"PMC_1918979","title":"Macrophage inflammatory protein (MIP)-1 beta abrogates the capacity of MIP-1 alpha to suppress myeloid progenitor cell growth.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1918979","citation_count":90,"is_preprint":false},{"pmid":"10888363","id":"PMC_10888363","title":"Expression of the beta-chemokines RANTES and MIP-1 beta by human brain microvessel endothelial cells in primary culture.","date":"2000","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10888363","citation_count":84,"is_preprint":false},{"pmid":"7093302","id":"PMC_7093302","title":"Evidence for aldehydes bound to liver microsomal protein following CCl4 or BrCCl3 poisoning.","date":"1982","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/7093302","citation_count":83,"is_preprint":false},{"pmid":"9129172","id":"PMC_9129172","title":"Tissue injury and repair as parallel and opposing responses to CCl4 hepatotoxicity: a novel dose-response.","date":"1997","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/9129172","citation_count":81,"is_preprint":false},{"pmid":"29722145","id":"PMC_29722145","title":"High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma.","date":"2018","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29722145","citation_count":79,"is_preprint":false},{"pmid":"32382083","id":"PMC_32382083","title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.","date":"2020","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/32382083","citation_count":77,"is_preprint":false},{"pmid":"20550952","id":"PMC_20550952","title":"Prevention of CCl4-induced nephrotoxicity with Sonchus asper in rat.","date":"2010","source":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","url":"https://pubmed.ncbi.nlm.nih.gov/20550952","citation_count":75,"is_preprint":false},{"pmid":"26921731","id":"PMC_26921731","title":"Protective effect of wedelolactone against CCl4-induced acute liver injury in mice.","date":"2016","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26921731","citation_count":71,"is_preprint":false},{"pmid":"23236235","id":"PMC_23236235","title":"Hepatoprotective effects of baicalein against CCl₄-induced acute liver injury in mice.","date":"2012","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/23236235","citation_count":71,"is_preprint":false},{"pmid":"17442287","id":"PMC_17442287","title":"Mathematical modelling of liver regeneration after intoxication with CCl(4).","date":"2007","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/17442287","citation_count":70,"is_preprint":false},{"pmid":"2814225","id":"PMC_2814225","title":"Protection of hepatotoxic and lethal effects of CCl4 by partial hepatectomy.","date":"1989","source":"Toxicologic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/2814225","citation_count":67,"is_preprint":false},{"pmid":"36914687","id":"PMC_36914687","title":"Mangiferin relieves CCl4-induced liver fibrosis in mice.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36914687","citation_count":65,"is_preprint":false},{"pmid":"26203686","id":"PMC_26203686","title":"MicroRNA-125b and chemokine CCL4 expression are associated with calcific aortic valve disease.","date":"2015","source":"Annals of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26203686","citation_count":63,"is_preprint":false},{"pmid":"19620252","id":"PMC_19620252","title":"An arrestin-dependent multi-kinase signaling complex mediates MIP-1beta/CCL4 signaling and chemotaxis of primary human macrophages.","date":"2009","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/19620252","citation_count":62,"is_preprint":false},{"pmid":"29993036","id":"PMC_29993036","title":"PSTPIP2 connects DNA methylation to macrophage polarization in CCL4-induced mouse model of hepatic fibrosis.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29993036","citation_count":62,"is_preprint":false},{"pmid":"16799993","id":"PMC_16799993","title":"Induction of Gas6 protein in CCl4-induced rat liver injury and anti-apoptotic effect on hepatic stellate cells.","date":"2006","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/16799993","citation_count":61,"is_preprint":false},{"pmid":"12218153","id":"PMC_12218153","title":"Activation of monocytic cells through Fc gamma receptors induces the expression of macrophage-inflammatory protein (MIP)-1 alpha, MIP-1 beta, and RANTES.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12218153","citation_count":59,"is_preprint":false},{"pmid":"18068155","id":"PMC_18068155","title":"Fucoidan partly prevents CCl4-induced liver fibrosis.","date":"2007","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18068155","citation_count":56,"is_preprint":false},{"pmid":"8531136","id":"PMC_8531136","title":"Inactivation and degradation of human cytochrome P4502E1 by CCl4 in a transfected HepG2 cell line.","date":"1995","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/8531136","citation_count":56,"is_preprint":false},{"pmid":"27748906","id":"PMC_27748906","title":"Hypoxia and macrophages promote glioblastoma invasion by the CCL4-CCR5 axis.","date":"2016","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/27748906","citation_count":54,"is_preprint":false},{"pmid":"2451632","id":"PMC_2451632","title":"Changes in albumin, alpha-fetoprotein and collagen gene transcription in CCl4-induced hepatic fibrosis.","date":"1988","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/2451632","citation_count":52,"is_preprint":false},{"pmid":"25620312","id":"PMC_25620312","title":"MicroRNA-125b modulates inflammatory chemokine CCL4 expression in immune cells and its reduction causes CCL4 increase with age.","date":"2015","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/25620312","citation_count":50,"is_preprint":false},{"pmid":"32911750","id":"PMC_32911750","title":"CCL4 Inhibition in Atherosclerosis: Effects on Plaque Stability, Endothelial Cell Adhesiveness, and Macrophages Activation.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32911750","citation_count":49,"is_preprint":false},{"pmid":"25412679","id":"PMC_25412679","title":"CCl4 induced genotoxicity and DNA oxidative damages in rats: hepatoprotective effect of Sonchus arvensis.","date":"2014","source":"BMC complementary and alternative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25412679","citation_count":49,"is_preprint":false},{"pmid":"6154986","id":"PMC_6154986","title":"Functional and biochemical correlates of chlordecone exposure and its enhancement of CCl4 hepatotoxicity.","date":"1980","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/6154986","citation_count":49,"is_preprint":false},{"pmid":"12070155","id":"PMC_12070155","title":"Natural truncation of the chemokine MIP-1 beta /CCL4 affects receptor specificity but not anti-HIV-1 activity.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12070155","citation_count":47,"is_preprint":false},{"pmid":"1824173","id":"PMC_1824173","title":"Colchicine antimitosis abolishes CCl4 autoprotection.","date":"1991","source":"Toxicologic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/1824173","citation_count":46,"is_preprint":false},{"pmid":"28656247","id":"PMC_28656247","title":"Macrophage-derived foam cells impair endothelial barrier function by inducing endothelial-mesenchymal transition via CCL-4.","date":"2017","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28656247","citation_count":46,"is_preprint":false},{"pmid":"34755124","id":"PMC_34755124","title":"CCL4 induces inflammatory signalling and barrier disruption in the neurovascular endothelium.","date":"2021","source":"Brain, behavior, & immunity - health","url":"https://pubmed.ncbi.nlm.nih.gov/34755124","citation_count":45,"is_preprint":false},{"pmid":"15634233","id":"PMC_15634233","title":"Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies.","date":"2005","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/15634233","citation_count":45,"is_preprint":false},{"pmid":"10070039","id":"PMC_10070039","title":"Transplanted hepatocytes proliferate differently after CCl4 treatment and hepatocyte growth factor infusion.","date":"1999","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10070039","citation_count":45,"is_preprint":false},{"pmid":"24910408","id":"PMC_24910408","title":"Reversing effects of lignans on CCl4-induced hepatic CYP450 down regulation by attenuating oxidative stress.","date":"2014","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24910408","citation_count":44,"is_preprint":false},{"pmid":"16552806","id":"PMC_16552806","title":"Therapeutic effect of interleukin-10 on CCl4-induced hepatic fibrosis in rats.","date":"2006","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/16552806","citation_count":42,"is_preprint":false},{"pmid":"6192011","id":"PMC_6192011","title":"Acute hepatotoxicity and lethality of CCl4 in chlordecone-pretreated rats.","date":"1983","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/6192011","citation_count":40,"is_preprint":false},{"pmid":"24349218","id":"PMC_24349218","title":"Attenuation of CCl4-induced hepatic fibrosis in mice by vaccinating against TGF-β1.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24349218","citation_count":40,"is_preprint":false},{"pmid":"29717113","id":"PMC_29717113","title":"CCL4 enhances preosteoclast migration and its receptor CCR5 downregulation by RANKL promotes osteoclastogenesis.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29717113","citation_count":39,"is_preprint":false},{"pmid":"15843566","id":"PMC_15843566","title":"Multiple products derived from two CCL4 loci: high incidence of a new polymorphism in HIV+ patients.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15843566","citation_count":38,"is_preprint":false},{"pmid":"11536240","id":"PMC_11536240","title":"MIP-1 alpha and MIP-1 beta induction by dengue virus.","date":"2001","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/11536240","citation_count":38,"is_preprint":false},{"pmid":"24096707","id":"PMC_24096707","title":"Inhibitory effect of gallic acid on CCl4-mediated liver fibrosis in mice.","date":"2014","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/24096707","citation_count":37,"is_preprint":false},{"pmid":"26742567","id":"PMC_26742567","title":"Resveratrol can prevent CCl₄-induced liver injury by inhibiting Notch signaling pathway.","date":"2016","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/26742567","citation_count":37,"is_preprint":false},{"pmid":"20830702","id":"PMC_20830702","title":"Morphological and molecular pathology of CCL4-induced hepatic fibrosis in connexin43-deficient mice.","date":"2010","source":"Microscopy research and technique","url":"https://pubmed.ncbi.nlm.nih.gov/20830702","citation_count":36,"is_preprint":false},{"pmid":"8510794","id":"PMC_8510794","title":"Fever and feeding: differential actions of macrophage inflammatory protein-1 (MIP-1), MIP-1 alpha and MIP-1 beta on rat hypothalamus.","date":"1993","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/8510794","citation_count":35,"is_preprint":false},{"pmid":"36460296","id":"PMC_36460296","title":"Sini San ameliorates CCl4-induced liver fibrosis in mice by inhibiting AKT-mediated hepatocyte apoptosis.","date":"2022","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36460296","citation_count":34,"is_preprint":false},{"pmid":"30854716","id":"PMC_30854716","title":"Critical role of CCL4 in eosinophil recruitment into the airway.","date":"2019","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30854716","citation_count":34,"is_preprint":false},{"pmid":"16407404","id":"PMC_16407404","title":"Conditional dominant mutations in the Caenorhabditis elegans gene act-2 identify cytoplasmic and muscle roles for a redundant actin isoform.","date":"2006","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/16407404","citation_count":34,"is_preprint":false},{"pmid":"17327452","id":"PMC_17327452","title":"CCL4 protects from type 1 diabetes by altering islet beta-cell-targeted inflammatory responses.","date":"2007","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/17327452","citation_count":33,"is_preprint":false},{"pmid":"16287062","id":"PMC_16287062","title":"Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival.","date":"2006","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16287062","citation_count":33,"is_preprint":false},{"pmid":"2590162","id":"PMC_2590162","title":"Protective role of fructose 1,6-bisphosphate during CCl4 hepatotoxicity in rats.","date":"1989","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/2590162","citation_count":33,"is_preprint":false},{"pmid":"16988274","id":"PMC_16988274","title":"Cytokine and chemokine transcription profile during Mycoplasma pulmonis infection in susceptible and resistant strains of mice: macrophage inflammatory protein 1beta (CCL4) and monocyte chemoattractant protein 2 (CCL8) and accumulation of CCR5+ Th cells.","date":"2006","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16988274","citation_count":33,"is_preprint":false},{"pmid":"27586651","id":"PMC_27586651","title":"Hepatocyte ERBB3 and EGFR are required for maximal CCl4-induced liver fibrosis.","date":"2016","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27586651","citation_count":32,"is_preprint":false},{"pmid":"12388182","id":"PMC_12388182","title":"Taurocholate feeding prevents CCl4-induced damage of large cholangiocytes through PI3-kinase-dependent mechanism.","date":"2002","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12388182","citation_count":32,"is_preprint":false},{"pmid":"23951204","id":"PMC_23951204","title":"Oroxylin A accelerates liver regeneration in CCl₄-induced acute liver injury mice.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23951204","citation_count":32,"is_preprint":false},{"pmid":"36690176","id":"PMC_36690176","title":"The FDA modernisation act 2.0: Bringing non-animal technologies to the regulatory table.","date":"2023","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/36690176","citation_count":31,"is_preprint":false},{"pmid":"19424597","id":"PMC_19424597","title":"Expression of angiotensin-converting enzyme 2 in CCL4-induced rat liver fibrosis.","date":"2009","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19424597","citation_count":31,"is_preprint":false},{"pmid":"21614014","id":"PMC_21614014","title":"CCL4L polymorphisms and CCL4/CCL4L serum levels are associated with psoriasis severity.","date":"2011","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/21614014","citation_count":31,"is_preprint":false},{"pmid":"15052689","id":"PMC_15052689","title":"Ginkgo biloba extract reverses CCl4-induced liver fibrosis in rats.","date":"2004","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/15052689","citation_count":31,"is_preprint":false},{"pmid":"34628485","id":"PMC_34628485","title":"p53-mediated redox control promotes liver regeneration and maintains liver function in response to CCl4.","date":"2021","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/34628485","citation_count":31,"is_preprint":false},{"pmid":"34884541","id":"PMC_34884541","title":"CCL4 Stimulates Cell Migration in Human Osteosarcoma via the mir-3927-3p/Integrin αvβ3 Axis.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34884541","citation_count":30,"is_preprint":false},{"pmid":"27233360","id":"PMC_27233360","title":"Proficiencies of Artemisia scoparia against CCl4 induced DNA damages and renal toxicity in rat.","date":"2016","source":"BMC complementary and alternative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27233360","citation_count":30,"is_preprint":false},{"pmid":"26170860","id":"PMC_26170860","title":"Blockade of CCN4 attenuates CCl4-induced liver fibrosis.","date":"2015","source":"Archives of medical science : AMS","url":"https://pubmed.ncbi.nlm.nih.gov/26170860","citation_count":29,"is_preprint":false},{"pmid":"21731074","id":"PMC_21731074","title":"Status epilepticus evokes prolonged increase in the expression of CCL3 and CCL4 mRNA and protein in the rat brain.","date":"2011","source":"Acta neurobiologiae experimentalis","url":"https://pubmed.ncbi.nlm.nih.gov/21731074","citation_count":29,"is_preprint":false},{"pmid":"10540332","id":"PMC_10540332","title":"The assignment of chemokine-chemokine receptor pairs: TARC and MIP-1 beta are not ligands for human CC-chemokine receptor 8.","date":"1999","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10540332","citation_count":29,"is_preprint":false},{"pmid":"27322257","id":"PMC_27322257","title":"MicroRNA Expression Profiling in CCl₄-Induced Liver Fibrosis of Mus musculus.","date":"2016","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27322257","citation_count":28,"is_preprint":false},{"pmid":"23760235","id":"PMC_23760235","title":"Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote Epstein-Barr virus-triggered B cell proliferation.","date":"2013","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/23760235","citation_count":28,"is_preprint":false},{"pmid":"27168353","id":"PMC_27168353","title":"Deferoxamine alleviates liver fibrosis induced by CCl4 in rats.","date":"2016","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27168353","citation_count":28,"is_preprint":false},{"pmid":"23999088","id":"PMC_23999088","title":"Berberine and S allyl cysteine mediated amelioration of DEN+CCl4 induced hepatocarcinoma.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23999088","citation_count":28,"is_preprint":false},{"pmid":"15095403","id":"PMC_15095403","title":"Amino-terminal processing of MIP-1beta/CCL4 by CD26/dipeptidyl-peptidase IV.","date":"2004","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15095403","citation_count":27,"is_preprint":false},{"pmid":"28447731","id":"PMC_28447731","title":"Vatalanib, a tyrosine kinase inhibitor, decreases hepatic fibrosis and sinusoidal capillarization in CCl4-induced fibrotic mice.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28447731","citation_count":27,"is_preprint":false},{"pmid":"12427015","id":"PMC_12427015","title":"Characterization of the role of the N-loop of MIP-1 beta in CCR5 binding.","date":"2002","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12427015","citation_count":27,"is_preprint":false},{"pmid":"28415630","id":"PMC_28415630","title":"Resveratrol alleviates FFA and CCl4 induced apoptosis in HepG2 cells via restoring endoplasmic reticulum stress.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28415630","citation_count":27,"is_preprint":false},{"pmid":"2205557","id":"PMC_2205557","title":"Mitochondrial structure and function in CCl4-induced cirrhosis in the rat.","date":"1990","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/2205557","citation_count":27,"is_preprint":false},{"pmid":"24009828","id":"PMC_24009828","title":"Isorhamnetin-3-O-galactoside Protects against CCl4-Induced Hepatic Injury in Mice.","date":"2012","source":"Biomolecules & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24009828","citation_count":26,"is_preprint":false},{"pmid":"26045230","id":"PMC_26045230","title":"Comparison of TGF-β, PDGF, and CTGF in hepatic fibrosis models using DMN, CCl4, and TAA.","date":"2015","source":"Drug and chemical toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/26045230","citation_count":25,"is_preprint":false},{"pmid":"21978833","id":"PMC_21978833","title":"Neutralization of chemokine CXCL14 (BRAK) expression reduces CCl4 induced liver injury and steatosis in mice.","date":"2011","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21978833","citation_count":25,"is_preprint":false},{"pmid":"12706302","id":"PMC_12706302","title":"Changes in activin and activin receptor subunit expression in rat liver during the development of CCl4-induced cirrhosis.","date":"2003","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12706302","citation_count":25,"is_preprint":false},{"pmid":"27819329","id":"PMC_27819329","title":"mTOR Overactivation in Mesenchymal cells Aggravates CCl4- Induced liver Fibrosis.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27819329","citation_count":25,"is_preprint":false},{"pmid":"2193098","id":"PMC_2193098","title":"Identification of cell surface receptors for the Act-2 cytokine.","date":"1990","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2193098","citation_count":23,"is_preprint":false},{"pmid":"11222690","id":"PMC_11222690","title":"Increased expression of MIP-1 alpha and MIP-1 beta mRNAs in the brain correlates spatially and temporally with the spongiform neurodegeneration induced by a murine oncornavirus.","date":"2001","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/11222690","citation_count":23,"is_preprint":false},{"pmid":"25824458","id":"PMC_25824458","title":"Anti-fibrotic effect of plumbagin on CCl₄-lesioned rats.","date":"2015","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25824458","citation_count":23,"is_preprint":false},{"pmid":"25636406","id":"PMC_25636406","title":"Structures of human CCL18, CCL3, and CCL4 reveal molecular determinants for quaternary structures and sensitivity to insulin-degrading enzyme.","date":"2015","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25636406","citation_count":22,"is_preprint":false},{"pmid":"30021348","id":"PMC_30021348","title":"Protective aptitude of Periploca hydaspidis Falc against CCl4 induced hepatotoxicity in experimental rats.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30021348","citation_count":21,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53700,"output_tokens":7417,"usd":0.136178,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16880,"output_tokens":3890,"usd":0.090825,"stage2_stop_reason":"end_turn"},"total_usd":0.227003,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"CCL4 (MIP-1β), together with RANTES and MIP-1α, was identified as a major HIV-suppressive factor produced by CD8+ T cells. Recombinant CCL4 induced dose-dependent inhibition of HIV-1, HIV-2, and SIV infection, and neutralizing antibodies against all three chemokines completely blocked HIV-suppressive activity in CD8+ T cell supernatants.\",\n      \"method\": \"Protein purification from CD8+ T cell culture supernatants, sequence identification, recombinant protein functional assay, neutralizing antibody blockade\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (purification, sequencing, recombinant protein assay, antibody neutralization), widely replicated finding\",\n      \"pmids\": [\"8525373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CCL4 (MIP-1β), when immobilized on proteoglycan (heparin-BSA conjugate or CD44 proteoglycan), induces T cell adhesion to VCAM-1, preferentially augmenting adhesion of CD8+ T cells. CCL4 is present on lymph node endothelium in vivo, suggesting proteoglycan-mediated presentation on endothelial surfaces.\",\n      \"method\": \"In vitro T cell adhesion assay with immobilized chemokine on proteoglycan substrates, immunolocalization of CCL4 on lymph node endothelium\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct functional adhesion assay plus in vivo localization, published in Nature with broad replication\",\n      \"pmids\": [\"7678446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CCL4 (MIP-1β) acts as a potent chemoattractant for activated T lymphocytes, with preferential chemotactic activity toward CD4+ T cells, and enhances T cell binding to endothelial cell monolayers.\",\n      \"method\": \"In vitro microchemotaxis (Boyden chamber) assay with recombinant human MIP-1β on activated and resting T cell subsets; endothelial adhesion assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated by multiple independent labs using in vitro chemotaxis assays\",\n      \"pmids\": [\"7682337\", \"7684437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CCL4 (MIP-1β) preferentially attracts CD4+ T lymphocytes (with some preference for naive CD45RA phenotype) in microchemotaxis assays, while CCL3 (MIP-1α) has broader lymphocyte chemoattractant activity including B cells and cytotoxic T cells.\",\n      \"method\": \"In vitro microchemotaxis assay comparing recombinant MIP-1α and MIP-1β across lymphocyte subpopulations\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct comparative functional assay, replicated across independent labs\",\n      \"pmids\": [\"7684437\", \"7682337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"CCL4 (MIP-1β) blocks the suppressive activity of MIP-1α on myeloid progenitor cell (BFU-E, CFU-GEMM, CFU-GM) colony formation. Pulse treatment showed CCL4 must act before or simultaneously with MIP-1α; the antagonism is specific (CCL4 does not block H-ferritin suppression).\",\n      \"method\": \"Bone marrow colony formation assay with recombinant murine MIP-1β and MIP-1α, pulse-treatment experiments, specificity controls with H-ferritin\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean in vitro functional assay with specificity controls, single lab\",\n      \"pmids\": [\"1918979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CCL4 (MIP-1β) elicits weak monocyte chemotaxis and minimal degranulation (N-acetyl-β-D-glucosaminidase release) compared to MCP-1 and MIP-1α. Cross-desensitization experiments using intracellular Ca2+ changes and binding competition with radiolabeled MIP-1α showed that MIP-1β shares receptors with RANTES and MIP-1α but not with MCP-1/2/3.\",\n      \"method\": \"In vitro monocyte chemotaxis, degranulation, Ca2+ flux, receptor desensitization, and radiolabeled ligand competition binding assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal biochemical assays in a single rigorous study establishing receptor sharing\",\n      \"pmids\": [\"7531149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCL4 is the most potent chemoattractant for CD4+CD25+ regulatory T cells produced by activated B cells and professional APCs. Depletion of CCL4 led to a deregulated humoral response and production of autoantibodies, establishing CCL4 as a mediator of regulatory T cell recruitment to B cells and APCs.\",\n      \"method\": \"Gene expression profiling to identify chemokines, chemotaxis assays, CCL4 depletion experiments, analysis of humoral immune response\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional in vivo depletion plus in vitro chemotaxis, published in Nature Immunology\",\n      \"pmids\": [\"11702067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCL4 (MIP-1β) can function as a monomer for CCR5 binding and activation. Monomeric mutants (P8A, N-terminally truncated MIP(9)) retained CCR5 binding (Ki ~480–600 pM) and the ability to activate CCR5 (induce Ca2+ release). Phe13, the residue immediately after the conserved CC motif, is a key determinant for CCR5 binding; substitution with Tyr, Leu, Lys, or Ala reduced both binding affinity and receptor activation.\",\n      \"method\": \"NMR spectroscopy, analytical ultracentrifugation, CCR5 receptor binding assays, intracellular Ca2+ release assay in CCR5-transfected CHO cells, mutagenesis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution with mutagenesis, NMR structural validation, and functional receptor assays in a single study\",\n      \"pmids\": [\"10727234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The naturally occurring N-terminally truncated form of CCL4 (MIP-1β(3-69)), secreted by activated human peripheral blood lymphocytes, retains the ability to downregulate CCR5 surface expression and inhibit CCR5-mediated HIV-1 entry. Unlike full-length CCL4, MIP-1β(3-69) also triggers Ca2+ responses via CCR1 and CCR2b, indicating expanded receptor specificity upon truncation.\",\n      \"method\": \"Affinity purification of native truncated protein from lymphocyte supernatants, mass spectrometry structural confirmation, CCR5 downmodulation assay, HIV entry inhibition assay, Ca2+ signaling assays through CCR1, CCR2b, and CCR5\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — purification of native protein, structural confirmation by MS, multiple functional receptor assays, single lab\",\n      \"pmids\": [\"12070155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CD26/dipeptidyl-peptidase IV (DPPIV) cleaves full-length CCL4 (MIP-1β) at its N-terminus to generate the truncated form MIP-1β(3-69). Cleavage is blocked by DPPIV inhibitory peptides derived from HIV Tat(1-9) or TAX2-R(1-9). Kinetics of conversion in activated PBLs correlates with cell surface expression of CD26.\",\n      \"method\": \"Enzymatic cleavage assay with CD26/DPPIV, DPPIV inhibitory peptide blockade in cell culture, correlation of CD26 surface expression with conversion kinetics\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct enzymatic assay with inhibitor controls and cell-based confirmation, single lab\",\n      \"pmids\": [\"15095403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The N-loop residues Arg18, Lys19, and Arg22 of CCL4 (MIP-1β), along with Pro21, contribute to CCR5 binding through their positive charge. Tyr15 is necessary for proper chemokine folding. Binding determinants are arranged on one surface of the protein. Correlation between binding affinity and functional potency in Ca2+ assays confirms these residues are essential for CCR5 interaction.\",\n      \"method\": \"Site-directed mutagenesis, NMR spectroscopy (folding analysis), CCR5 receptor binding assay, Ca2+ mobilization functional assay\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis combined with NMR and two functional assays, single lab\",\n      \"pmids\": [\"12427015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL4 (MIP-1β) and CCL3 (MIP-1α) form rod-shaped, double-helical high-molecular-weight polymers as revealed by crystal structures. Polymerization buries receptor-binding sites, and depolymerization mutations enhance CCL3/CCL4 ability to arrest monocytes on activated endothelium but render them ineffective in mouse peritoneal cell recruitment. Insulin-degrading enzyme (IDE) selectively degrades monomeric CCL4/CCL3 but not polymers; decreased IDE expression leads to elevated CCL4 levels in microglial cells.\",\n      \"method\": \"Crystal structure determination, biophysical analyses (sedimentation, DLS), mathematical modeling, depolymerization mutagenesis, monocyte arrest assays, peritoneal cell recruitment assay, proteomic identification of IDE, IDE knockdown in microglial cells\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus multiple orthogonal biophysical, functional, and cellular assays; single study with comprehensive mechanistic coverage\",\n      \"pmids\": [\"20959807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structure of CCL4 shows that Pro8, conserved in CCL4 and CCL3, is critical for oligomerization. The P8A mutation in CCL4 stabilizes a type 1 β-turn at the N-terminus, preventing dimerization by a mechanism distinct from that in CCL3. IDE degrades CCL3 and CCL4 but not CCL18 (which lacks Pro8), providing a structural basis for selective degradation.\",\n      \"method\": \"Crystal structure determination, small-angle X-ray scattering, mutagenesis (P8A), IDE degradation assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with SAXS and functional mutagenesis and enzymatic assays, single lab\",\n      \"pmids\": [\"25636406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCL4 (MIP-1β) signaling through CCR5 in primary human macrophages requires an arrestin-dependent multi-kinase complex. CCR5 stimulation by CCL4 triggers Pyk2 and PI3K p85 translocation from cytoplasm to colocalize with Lyn at the plasma membrane, forming a multimolecular complex. Arrestins are recruited into this complex; arrestin knockdown impairs complex formation and abolishes macrophage chemotaxis toward CCL4.\",\n      \"method\": \"siRNA gene silencing, pharmacological kinase inhibition, co-localization imaging, Co-IP/complex formation assays in primary human macrophages\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown plus pharmacological inhibition plus co-localization in primary human cells, multiple orthogonal approaches\",\n      \"pmids\": [\"19620252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Cell surface receptors for CCL4 (Act-2) were identified on activated peripheral blood lymphocytes and multiple cell lines (MT-2, HL60, HeLa, K562). The equilibrium dissociation constant (Kd) is 3–12 nM. A blocking polyclonal antiserum was developed that prevents Act-2 receptor binding.\",\n      \"method\": \"125I-labeled Act-2 radioligand binding assay, equilibrium binding analysis (Kd determination), blocking antiserum development\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct radiolabeled ligand binding with Kd determination and blocking antibody, single lab\",\n      \"pmids\": [\"2193098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In prostate tumorigenesis, macrophage androgen receptor (AR) upregulates CCL4 secretion, which activates STAT3 in epithelial cells, promoting epithelial-to-mesenchymal transition and downregulation of p53/PTEN. CCL4-neutralizing antibody blocked macrophage-induced tumorigenic signaling, and an AR degradation enhancer (ASC-J9) reduced CCL4 expression and xenograft tumor growth in vivo.\",\n      \"method\": \"Macrophage-epithelial cell co-culture tumorigenesis model, CCL4 neutralizing antibody, AR degradation enhancer treatment, xenograft in vivo model, PTEN+/- macrophage AR knockout mice\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple in vitro and in vivo models with antibody blockade, single lab\",\n      \"pmids\": [\"23878190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCL4 promotes trophoblast migration at the feto-maternal interface. CCR1 and CCR3 (CCL4 receptors) are expressed on extravillous trophoblasts. Trophoblast migration occurred in response to CCL4 in migration assays, and this was attenuated by neutralizing antibodies to CCL4 in endometrial cell-conditioned media.\",\n      \"method\": \"Immunolocalization of chemokine receptors in human implantation sites, RT-PCR for receptor expression, trophoblast cell line migration assay, neutralizing antibody inhibition\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct migration assay plus receptor localization plus neutralizing antibody, single lab\",\n      \"pmids\": [\"16452465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"miR-125b negatively regulates CCL4 expression in human immune cells (monocytes, naïve CD8 T cells) by targeting the 3'UTR seed sequence of CCL4 mRNA. shRNA knockdown of miR-125b increased CCL4 protein, while transfection of miR-125b reduced CCL4 mRNA and protein following stimulation. Reduced miR-125b in old adults correlates with elevated CCL4.\",\n      \"method\": \"shRNA knockdown of miR-125b in primary human immune cells, miR-125b overexpression by transfection, 3'UTR seed sequence validation, intracellular CCL4 protein measurement\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct gain- and loss-of-function experiments with 3'UTR validation, single lab\",\n      \"pmids\": [\"25620312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CCL4 secreted by M1 macrophage-derived foam cells induces endothelial-to-mesenchymal transition (EndMT) via CCR5, upregulating TGF-β expression, which increases endothelial permeability and monocyte adhesion. Anti-CCL4 antibody abolished EndMT; CCR5 antagonist and TGF-β knockdown reversed CCL4-induced EndMT.\",\n      \"method\": \"Protein array to identify CCL4, ELISA, anti-CCL4 antibody neutralization, CCR5 antagonist treatment, TGF-β siRNA knockdown, permeability assay, monocyte adhesion assay\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — antibody neutralization, receptor antagonist, and siRNA knockdown with multiple functional readouts, single lab\",\n      \"pmids\": [\"28656247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCL4 signals through CCR5 in blood-brain barrier endothelial cells to cause p38 phosphorylation, actin stress fiber formation, junctional ZO-1 reduction (~60% within 60 min), VE-cadherin internalisation, increased paracellular permeability in vitro and in vivo, and enhanced lymphocyte transmigration across endothelial monolayers.\",\n      \"method\": \"Western blot (p38 phosphorylation), immunofluorescence (ZO-1, VE-cadherin, F-actin), RITC-dextran flux permeability assay, transendothelial lymphocyte migration assay, in vivo pial microvessel occlusion technique, fluorescein angiography in mouse retinae\",\n      \"journal\": \"Brain, behavior, & immunity - health\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal functional and cellular assays in vitro and in vivo, single lab\",\n      \"pmids\": [\"34755124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Hypoxia-conditioned macrophages promote glioblastoma cell invasion via CCL4-CCR5 axis. Hypoxia upregulates CCR5 expression on GBM cells and elevates CCL4 secretion from macrophages via IRF-8. CCL4 from hypoxic macrophage supernatants enhanced GBM invasion and MMP-9 expression, and this effect was mediated through CCR5 signaling.\",\n      \"method\": \"GBM cell invasion assay, macrophage supernatant treatment, CCR5 expression analysis, CCL4 ELISA, IRF-8 involvement analysis\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, functional assay without direct genetic manipulation of CCL4 or full receptor pathway validation\",\n      \"pmids\": [\"27748906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CCL4 enhances preosteoclast cell migration and viability via CCR5. RANKL treatment rapidly downregulates CCR5 expression on preosteoclasts via MEK and JNK signaling, and this CCR5 downregulation promotes osteoclastogenesis. IFN-γ recovers CCR5 expression and antagonizes the pro-osteoclastogenic effect.\",\n      \"method\": \"CCL4 migration and viability assays in preosteoclast cells, CCR5 expression analysis upon RANKL treatment, MEK and JNK pharmacological inhibition, IFN-γ treatment, osteoclast differentiation assay\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — pharmacological inhibition of kinase pathway plus functional differentiation assay, single lab\",\n      \"pmids\": [\"29717113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CCL4 acts as a chemoattractant for eosinophils. IL-5-stimulated human eosinophils predominantly secrete CCL4. In a mouse model, administration of a CCL4-neutralizing antibody attenuated eosinophilic airway infiltration and airway hyperresponsiveness.\",\n      \"method\": \"In vitro eosinophil stimulation and CCL4 measurement, in vitro eosinophil chemotaxis assay, in vivo mouse model with CCL4-neutralizing antibody, airway hyperresponsiveness measurement\",\n      \"journal\": \"Clinical and experimental allergy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro chemotaxis plus in vivo antibody neutralization model, single lab\",\n      \"pmids\": [\"30854716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CCL4 delivery to NOD mice via plasmid vector protects against type 1 diabetes by suppressing CD8+ T cell recruitment to islets (with decreased CCR5 expression on CD8+ T cells), inducing a Th2-like response in spleen and pancreas, and promoting regulatory T cell activity in draining pancreatic lymph nodes. Antibody neutralization of CCL4 abrogated protection transferred by T cells from IL-4-treated NOD mice.\",\n      \"method\": \"Plasmid-based in vivo CCL4 delivery, CCL4 antibody neutralization, T cell transfer protection assay, flow cytometry of T cell subsets and CCR5 expression, Th1/Th2 cytokine profiling\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic delivery plus antibody neutralization plus immune phenotyping, single lab\",\n      \"pmids\": [\"17327452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"EBV latent membrane protein 1 (LMP1) upregulates CCL4 (and CCL3) in EBV-infected B cells via Jun N-terminal protein kinase (JNK) activation. Autocrine CCL4 and CCL3 are required for lymphoblastoid cell line (LCL) survival and proliferation; shRNA knockdown or neutralizing antibodies to CCL4/CCL3 suppressed cell proliferation and caused apoptosis.\",\n      \"method\": \"Cytokine antibody arrays, EBV-infection/LMP1 expression model, JNK inhibitor treatment, shRNA knockdown, neutralizing antibodies to CCL4/CCL3, proliferation and apoptosis assays\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — shRNA knockdown and neutralizing antibody with mechanistic pathway (LMP1-JNK-CCL4) established, single lab\",\n      \"pmids\": [\"23760235\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCL4 promotes osteosarcoma cell migration via CCR5, activating FAK, AKT, and HIF-1α signaling pathways, which downregulate miR-3927-3p, leading to upregulation of integrin αvβ3. Pharmacological inhibition of CCR5 with maraviroc prevented CCL4-induced integrin αvβ3 upregulation and cell migration.\",\n      \"method\": \"CCL4/CCR5 signaling pathway analysis, FAK/AKT/HIF-1α inhibitor treatment, miR-3927-3p expression analysis, integrin αvβ3 expression assay, CCR5 antagonist (maraviroc) treatment, cell migration assay\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological inhibition only without direct genetic manipulation of CCL4 pathway components, single lab\",\n      \"pmids\": [\"34884541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CCL4 (MIP-1β) does not bind to or signal through CCR8 at physiologically relevant concentrations. CCL4 did not bind CCR8 on stably transfected cells or on human Th2 cells, did not induce CCR8-mediated chemotaxis, and did not desensitize I-309-dependent Ca2+ mobilization through CCR8.\",\n      \"method\": \"CCR8-transfected cell line binding assay, chemotaxis assay, Ca2+ mobilization and receptor desensitization assay, binding on in vitro differentiated human CD4+ Th2 cells\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal receptor assays establishing a negative result with appropriate controls, single lab\",\n      \"pmids\": [\"10540332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Microinjection of CCL4 (MIP-1β) into the anterior hypothalamic preoptic area of rats evokes a monophasic fever (mean maximum ~2.1°C increase) and significantly attenuates food intake over 24 hours, demonstrating direct central nervous system actions on thermoregulation and feeding.\",\n      \"method\": \"Stereotaxic microinjection into rat anterior hypothalamus/preoptic area, body temperature telemetry, food and water intake monitoring\",\n      \"journal\": \"Neurochemical research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pharmacological administration without receptor identification or pathway mechanistic follow-up\",\n      \"pmids\": [\"8510794\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCL4 (MIP-1β/Act-2/SCYA4) is a CC chemokine that signals primarily through CCR5 (and, when N-terminally truncated by CD26/DPPIV, also through CCR1 and CCR2b) to drive chemotaxis of activated CD4+ and CD8+ T cells, monocytes/macrophages, regulatory T cells, and eosinophils; it inhibits HIV-1/HIV-2/SIV infection by competing for CCR5; it forms reversible rod-shaped double-helical polymers that protect it from selective degradation by insulin-degrading enzyme while burying its receptor-binding site; its CCR5 binding is mediated by Phe13 and N-loop residues Arg18, Lys19, and Arg22; and upon CCR5 engagement it assembles an arrestin-scaffolded Lyn/Pyk2/PI3K signaling complex to drive macrophage chemotaxis, activates p38-MAPK to disrupt blood-brain barrier tight junctions, and regulates diverse processes including myeloid progenitor suppression (antagonized by CCL3), endothelial-to-mesenchymal transition, regulatory T cell recruitment, osteoclast precursor migration, and EBV-driven B cell survival.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CCL4 (MIP-1β/Act-2) is a CC chemokine that directs the recruitment and adhesion of leukocytes—preferentially activated CD4+ and CD8+ T cells, monocytes, regulatory T cells, and eosinophils—during immune responses, and was identified as a major CD8+ T-cell-derived soluble factor that suppresses HIV-1, HIV-2, and SIV infection by competing for its receptor [#0, #2, #3, #22]. It functions chemotactically and, when immobilized on endothelial proteoglycan, promotes T-cell adhesion to VCAM-1, positioning it for leukocyte arrest on activated endothelium [#1, #2]. CCL4 signals principally through CCR5; binding is mediated by Phe13 immediately after the conserved CC motif and by positively charged N-loop residues Arg18, Lys19, and Arg22, with monomeric CCL4 sufficient for CCR5 binding and Ca2+-mobilizing activation [#7, #10]. CD26/DPPIV cleaves the N-terminus to generate MIP-1β(3-69), which retains CCR5 downmodulation and HIV-entry inhibition while acquiring expanded signaling through CCR1 and CCR2b [#8, #9]. Downstream of CCR5 in primary macrophages, CCL4 nucleates an arrestin-dependent multikinase complex of Lyn, Pyk2, and PI3K p85 at the plasma membrane that is required for chemotaxis [#13]. CCL4 (and CCL3) assemble into rod-shaped double-helical polymers whose formation depends on Pro8 and buries the receptor-binding surface; polymerization protects the chemokine from selective degradation by insulin-degrading enzyme, which cleaves only the monomeric forms [#11, #12]. Beyond leukocyte trafficking, CCL4–CCR5 signaling drives endothelial-to-mesenchymal transition via TGF-β and disrupts blood-brain-barrier tight junctions through p38 activation and loss of ZO-1/VE-cadherin [#18, #19], and CCL4 expression is post-transcriptionally restrained by miR-125b [#17]. CCL4 also antagonizes CCL3-mediated suppression of myeloid progenitor colony formation and mediates regulatory T-cell recruitment to B cells and APCs [#4, #6].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Establishing that CCL4 acts through specific cell-surface receptors was the first step in defining it as a signaling ligand rather than a generic secreted factor.\",\n      \"evidence\": \"125I-Act-2 radioligand equilibrium binding on activated PBLs and cell lines with blocking antiserum\",\n      \"pmids\": [\"2193098\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor identity not molecularly defined\", \"Downstream signaling not addressed\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"The finding that CCL4 antagonizes CCL3-mediated myeloid progenitor suppression revealed that closely related MIP-1 chemokines have opposing functional outputs.\",\n      \"evidence\": \"Bone marrow colony-formation assays with recombinant murine MIP-1β/MIP-1α, pulse treatments, H-ferritin specificity controls\",\n      \"pmids\": [\"1918979\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating antagonism not identified\", \"Single lab, murine system\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Defining CCL4 as a chemoattractant and adhesion-promoting factor for T-cell subsets, with proteoglycan-dependent endothelial presentation, established its core role in directing lymphocyte trafficking.\",\n      \"evidence\": \"Boyden-chamber chemotaxis on T-cell subsets, VCAM-1 adhesion assays with proteoglycan-immobilized chemokine, endothelial immunolocalization\",\n      \"pmids\": [\"7682337\", \"7684437\", \"7678446\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor not yet defined\", \"Molecular basis of adhesion augmentation unresolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identifying CCL4 as a CD8+ T-cell-derived HIV-suppressive factor and showing it shares receptors with RANTES and MIP-1α connected chemokine receptor usage to antiviral activity.\",\n      \"evidence\": \"Purification/sequencing from CD8+ T-cell supernatants, recombinant inhibition of HIV-1/2 and SIV, antibody neutralization; cross-desensitization and competition binding versus MCP-1\",\n      \"pmids\": [\"8525373\", \"7531149\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific receptor not yet named in these studies\", \"Mechanism of competition not structurally resolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Mapping Phe13 and N-loop residues and showing monomeric CCL4 is competent for CCR5 binding/activation defined the molecular determinants of receptor engagement.\",\n      \"evidence\": \"NMR, analytical ultracentrifugation, CCR5 binding and Ca2+ assays in CHO cells, mutagenesis (P8A, MIP(9), Phe13 substitutions, R18/K19/R22, Y15)\",\n      \"pmids\": [\"10727234\", \"12427015\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor-bound complex structure not determined\", \"Role of oligomerization in vivo unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrating that N-terminal truncation to MIP-1β(3-69) expands receptor specificity to CCR1/CCR2b while retaining anti-HIV CCR5 activity showed how processing reprograms CCL4 function.\",\n      \"evidence\": \"Native protein purification, mass spec, CCR5 downmodulation, HIV-entry inhibition, Ca2+ signaling via CCR1/CCR2b/CCR5\",\n      \"pmids\": [\"12070155\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological enzyme not identified in this study\", \"Relative in vivo abundance of truncated form unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identifying CD26/DPPIV as the protease generating MIP-1β(3-69) linked surface enzyme expression to in vivo control of CCL4 receptor specificity.\",\n      \"evidence\": \"Enzymatic cleavage assays, DPPIV inhibitory peptide blockade, correlation of CD26 surface expression with conversion in PBLs\",\n      \"pmids\": [\"15095403\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Quantitative contribution to in vivo signaling not established\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defining the arrestin-scaffolded Lyn/Pyk2/PI3K complex downstream of CCR5 established the intracellular machinery converting CCL4 binding into macrophage chemotaxis.\",\n      \"evidence\": \"siRNA silencing, kinase inhibition, co-localization imaging, Co-IP in primary human macrophages\",\n      \"pmids\": [\"19620252\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generalizability to other CCL4-responsive cells untested\", \"Order of complex assembly not fully resolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Discovery of double-helical CCL4 polymers and their protection from insulin-degrading enzyme revealed a structural switch controlling chemokine availability and presentation.\",\n      \"evidence\": \"Crystal structures, sedimentation/DLS, depolymerization mutants, monocyte arrest and peritoneal recruitment assays, IDE identification and microglial knockdown\",\n      \"pmids\": [\"20959807\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo trigger for polymer/monomer transition unclear\", \"Physiological balance of IDE degradation versus signaling unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Pinpointing Pro8 as the structural determinant of oligomerization and selective IDE degradation explained why CCL4/CCL3 but not CCL18 are IDE substrates.\",\n      \"evidence\": \"Crystal structure, SAXS, P8A mutagenesis, IDE degradation assays; plus miR-125b 3'UTR targeting of CCL4\",\n      \"pmids\": [\"25636406\", \"25620312\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of P8A oligomerization defect in vivo not tested\", \"miR-125b regulation mapped in limited cell types\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing CCL4–CCR5 disrupts endothelial junctions via p38 and drives EndMT via TGF-β extended CCL4 function from leukocyte recruitment to direct modulation of vascular barriers.\",\n      \"evidence\": \"Western blot, immunofluorescence (ZO-1, VE-cadherin, F-actin), permeability and transmigration assays in vitro and in vivo; CCR5 antagonist and TGF-β siLNA in EndMT model\",\n      \"pmids\": [\"34755124\", \"28656247\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab per study\", \"Relative contribution to disease pathology not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CCL4 polymerization, CD26-mediated truncation, and receptor selection are integrated to set context-specific responses (T-cell trafficking versus tumor, vascular, and bone microenvironments) remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structure of CCL4 bound to CCR5\", \"In vivo determinants of monomer/polymer and full-length/truncated balance unknown\", \"Mechanisms beyond CCR5 in non-immune contexts incompletely defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 2, 7, 10]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [7, 13, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 6, 22]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 2, 6, 22]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 13, 19]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CCR5\", \"CCR1\", \"CCR2b\", \"CD26\", \"IDE\", \"CCL3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}